BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2015 3:31:00 PM | Browse: 1298 | Download: 1519
 |
Received |
|
2014-12-24 09:19 |
 |
Peer-Review Started |
|
2014-12-26 15:28 |
 |
To Make the First Decision |
|
2015-02-07 14:54 |
 |
Return for Revision |
|
2015-02-10 14:13 |
 |
Revised |
|
2015-03-12 05:35 |
 |
Second Decision |
|
2015-09-02 15:39 |
 |
Accepted by Journal Editor-in-Chief |
|
2015-09-04 22:48 |
 |
Accepted by Executive Editor-in-Chief |
|
2015-09-08 15:52 |
 |
Articles in Press |
|
2015-09-08 15:52 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-09-25 21:22 |
 |
Publish the Manuscript Online |
|
2015-10-13 15:31 |
ISSN |
1948-9358 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Review |
Article Title |
Treatment of prediabetes
|
Manuscript Source |
Invited Manuscript |
All Author List |
Mustafa Kanat, Ralph A DeFronzo and Muhammad A Abdul-Ghani |
Funding Agency and Grant Number |
|
Corresponding Author |
Dr. Mustafa Kanat, MD, Division of Diabetes, Department of Internal Medicine, Istanbul Medipol University, TEM Avrupa Otoyolu Göztepe Çıkışı No: 1, Bağcılar, 34214 Istanbul, Turkey. mustafa.kanat@gmail.com
|
Key Words |
Prediabetes; Impaired fasting glucose; Impared glucose tolerance; Diabetes prevention; Type 2 diabetes mellitus |
Core Tip |
Behavioral changes (dieting plus exercising) are effective in preventing impaired glucose tolerance (GT)-type 2 diabetes mellitus (type 2 DM) conversion as well as impaired fasting glucose (FG) - type 2 DM conversion but loosing weight is hard and also difficult to maintain. Pharmacological interventions (plus dieting and exer-cising) improving and preserving beta-cell function and enhancing insulin sensitivity may be suitable choices for high-risk IGT patients. Troglitazone in Prevention of Diabetes Study, Pioglitazone in Prevention of Diabetes Study, Diabetes Reduction Assessment with ramipril and rosiglitazone Medication Trial, Actos Now for the prevention of diabetes study and Diabetes Prevention Program have proven that thiazolidinediones obviously prevent the development of type 2 DM in IGT subjects as well as IFG subjects. In Diabetes Prevention Program and Indian Diabetes Prevention Program, metformin slowed down the progression of IGT to type 2 DM, and eventually American Diabetes Association Consensus Conference Statement proposed metfor-min usage in high-risk IGT individuals. However, the efficacy of pioglitazone and rosiglitazone efficacy in preventing IGT progression to type 2 DM nearly doubles metformin’s efficacy (31% vs 72% and 62%, respectively). Rosiglitazone (low dose = 2 mg/d) together with metformin (850 mg/d) was proven to slow down IGT progression to type 2 DM as well as being more tolerable.
|
Publish Date |
2015-10-13 15:31 |
Citation |
Kanat M, DeFronzo RA, Abdul-Ghani MA. Treatment of prediabetes. World J Diabetes 2015; 6(12): 1207-1222 |
URL |
http://www.wjgnet.com/1948-9358/full/v6/i12/1207.htm |
DOI |
http://dx.doi.org/10.4239/wjd.v6.i12.1207 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345